UBC has worked extensively with emerging companies that might have developed a first compound, applied a technology to a specific therapeutic area or purchased a compound for which several trials have already been completed. In this last instance, UBC often helps with program/portfolio management of legacy and current studies.
We recognize that the long-term success of an emerging company is often based on the success of a single trial or the strategic development of subsequent trials. Moreover, we understand how crucial it is to plan and implement flawlessly – from clinical development to regulatory strategy to trial execution. That’s why we establish close partnerships with these clients, collaborating on everything requested, from big picture thinking to the critical minutiae of operational planning. As part of this, we share our state-of-the-art technology platforms to bring the latest and best tools to the table.
In short, because they are especially attuned to the kinds of counsel that might be required, our team members know what kinds of expertise are needed to optimize every aspect of your program.